Moderna Agrees to First Acquisition for $85 Million

Moderna, Inc. is set to acquire OriCiro Genomics K.K. for $85 million, who will provide expertise on cell-free DNA synthesis and amplification technologies.

“With this acquisition, we obtain best-in-class tools for cell-free DNA synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” commented Stéphane Bancel, Chief Executive Officer of Moderna.

2022 was a pivotal year for Moderna, the company‘s CEO noted in a recent statement. Moderna’s two Omicron-targeting bivalent COVID-19 vaccines have been approved in more than 70 countries. Its platform technology also delivered the world’s first-ever mRNA cancer treatment that showed efficacy in a randomised Phase II study, demonstrating the potential of personalised medicine.

Read the source article at europeanpharmaceuticalreview.com